EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Evidence-Based Medicine 2006;11:145; doi:10.1136/ebm.11.5.145
Copyright © 2006 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clase, C.
Right arrow Articles by Garg, A. X
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clase, C.
Right arrow Articles by Garg, A. X

Therapeutics

Review: the renoprotective effects of ACE inhibitors and ARBs independent of blood pressure control are uncertain

Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026–33.[CrossRef][Medline]

Q Do angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have renoprotective effects independent of blood pressure (BP) control?

Clinical impact ratings GP/FP/Primary care ******{star} IM/Ambulatory care *****{star}{star} Nephrology ******{star} Endocrine *****{star}{star}

Key Words: angiotensin converting enzyme inhibitors • antihypertensive agents • diabetic nephropathies • kidney failure (chronic) • renin-angiotensin system

The first 150 words of the full text of this article appear below.

METHODS
Formula Data sources: Medline, EMBASE/Excerpta Medica, and the Cochrane Library (1960 to January 2005); and references of relevant studies and reviews.

Formula Study selection and assessment: randomised controlled trials (RCTs) with >=1 year follow up that examined the effect of drug treatment with a BP lowering action on progression of renal disease. 127 RCTs (150 comparisons) with mean follow up of 4.2 years met the selection criteria.

Formula Outcomes: end stage renal disease (ESRD) (need for kidney transplantation or dialysis) and doubling of serum creatinine.

MAIN RESULTS
Changes in BP were similar across the 5 outcomes; all but 1 showed no difference in the degree of change in systolic and diastolic BP between patients receiving ACE inhibitors or ARBs and those receiving other antihypertensive drugs; ACE inhibitor or ARB treatment led to a reduction in systolic BP of 1.49 mm Hg (95% CI 0.05 to 2.92) in studies with change in creatinine concentration as an . . . [Full text of this article]

Catherine Clase, MB, BChir1, Amit X Garg, MD, PhD2

1 McMaster University, Hamilton, Ontario, Canada
2 University of Western Ontario, London, Ontario, Canada







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd.